The multinational pharmaceutical company will implement LifeSphere NavaX to harness cutting-edge Generative AI (GenAI) and redefine efficiency in Pharmacovigilance operations.

Boston, Massachusetts, USA – December 20, 2024 –

ArisGlobal, an innovative technology company at the forefront of life sciences and creator of LifeSphere®, today announced a top pharmaceutical company has chosen LifeSphere NavaX, the next-generation cognitive automation engine, to harness cutting-edge technologies including Generative AI (GenAI). This marks the fourth NavaX commercial agreement secured since its launch and productization in early 2024.  

The organization, who currently utilizes LifeSphere Safety and Regulatory interoperable platforms, will integrate NavaX into their Safety operations, streamlining end-to-end processes, drastically reducing manual workloads, and realizing significant return on investment (ROI). NavaX will automate critical tasks, such as case intake, literature review, signalling, and more.  

The organization will go live with NavaX within months, Spring 2025. The company has also considered a comprehensive change management approach, leveraging ArisGlobal’s Consulting Services to drive adoption across all functions. This strategy ensures that global teams are equipped to maximize the potential of this transformative technology. 

Ann-Marie Orange, ArisGlobal’s CIO and Global Head of R&D, shares: 

“One of the most compelling features – and reason we see rapid adoption of NavaX – is the system-agnostic compatibility, allowing seamless integration with third-party or home-grown safety systems. This top pharmaceutical company exemplifies the forward-thinking approach necessary to advance global pharmacovigilance standards. As we move into 2025 where successful adoption of advanced technology is a must, ArisGlobal invites the global life sciences industry to embrace NavaX to revolutionize safety and regulatory processes like never before – achieving measurable outcomes in just a few months.”  

With four major deals secured for NavaX in 2024, this milestone underscores the platform’s pivotal role in reshaping pharmacovigilance processes. ArisGlobal continues to lead the way in delivering transformative innovation to the life sciences industry, empowering its customers to redefine efficiency and focus on what matters most: patient safety and regulatory compliance.  

About ArisGlobal

ArisGlobal, an innovative life sciences technology company and creator of LifeSphere®, is transforming the way today’s most successful life sciences companies develop breakthroughs and bring new products to market. Headquartered in the United States, ArisGlobal has regional offices in Europe, India, Japan, and China. For more updates, follow ArisGlobal on LinkedIn. www.arisglobal.com.